The Effect of Cerebrolysin on the Predictive Value of Baseline Prognostic Risk Score in Moderate and Severe Traumatic Brain Injury.
Adult
Amino Acids
/ pharmacology
Attention
/ drug effects
Brain Injuries, Traumatic
/ drug therapy
Cognition
/ drug effects
Executive Function
/ drug effects
Female
Humans
Male
Mental Status and Dementia Tests
Middle Aged
Predictive Value of Tests
Prognosis
Quality of Life
Recovery of Function
/ drug effects
Risk Factors
Stroop Test
Wechsler Scales
AIS - Abbreviated Injury Scale
BPRS - Baseline Prognostic Risk Score
CTT - Colour Trails Test
Cerebrolysin
GCS - Glasgow Coma Scale
GOSE - Glasgow Outcome Scale Extended
HADS - Hospital Anxiety and Depression Scale
IMPACT - The International Mission on Prognosis and Analysis of Clinical Trials in TBI
MMSE - Mini Mental State Examination
MRC CRASH - Medical Research Council Corticosteroid Randomization after Significant Head Injury
PSI DSC - Processing Speed Index Digit Symbol Coding
PSI SS - Processing Speed Index Symbol Search
PTA - post-traumatic amnesia
TBI - Traumatic Brain Injury
Traumatic brain injury
WAIS III - Wechsler Adult Intelligence Scale Third Edition.
cognitive outcome
prognostic
Journal
Journal of medicine and life
ISSN: 1844-3117
Titre abrégé: J Med Life
Pays: Romania
ID NLM: 101477617
Informations de publication
Date de publication:
Historique:
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
18
11
2020
Statut:
ppublish
Résumé
Cognitive dysfunction is a significant complaint among patients after moderate to severe traumatic brain injury (TBI), with devastating consequences on functional recovery and quality of life. Prognostic models allow a better assessment and management of neurotrauma patients. The aim of the study was to demonstrate the predictive value of the Baseline Prognostic Risk Score (BPRS) in moderate to severe TBI, in a sample of patients treated with neurotrophic factors. Eighty patients with moderate-severe TBI from the CAPTAIN II study were included in secondary data analysis. Patients received active treatment with Cerebrolysin, 50 mL per day for ten days, followed by two treatment cycles with 10 mL per day for ten days. BPRS was determined on admission; the age was recorded, and patients were evaluated using the following neurocognitive tests: Mini-Mental State Essay (MMSE), Wechsler Adult Intelligence Scale-Third Edition Processing Speed Index (WAIS-III PSI) and Stroop Colour Word Test-Victoria Version at 10, 30 and 90 days. Hierarchical regression analysis was performed to investigate the unique predictive value of BPRS on cognitive evolution, independent of age. BPRS independently predicted scores on the WAIS-III PSI DSCales and the Word subscale of the Stroop Colour Word Test at 90 days. Age was a significant predictor for all the investigated scales at 10, 30, and 90 days. This study demonstrates the predictive value of a validated prognostic model (BPRS) for medium-term neurocognitive outcomes in a sample of moderate-severe traumatic brain injury treated with neurotrophic factors.
Identifiants
pubmed: 33072197
doi: 10.25122/jml-2020-0146
pii: JMedLife-13-283
pmc: PMC7550150
doi:
Substances chimiques
Amino Acids
0
cerebrolysin
37KZM6S21G
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
283-288Informations de copyright
©Carol Davila University Press.
Références
Neurol Sci. 2020 May;41(5):1171-1181
pubmed: 31897941
J Neurosurg. 2017 Mar;126(3):796-804
pubmed: 27231979
Acta Neurochir (Wien). 1976;34(1-4):45-55
pubmed: 961490
Crit Care Med. 2012 May;40(5):1609-17
pubmed: 22511138
Pediatr Crit Care Med. 2014 Jul;15(6):569-70
pubmed: 25000423
PLoS Med. 2008 Aug 5;5(8):e165; discussion e165
pubmed: 18684008
J Neurotrauma. 2005 Oct;22(10):1025-39
pubmed: 16238481
PLoS Med. 2017 Jul 11;14(7):e1002331
pubmed: 28700588
J Neurotrauma. 2015 Jan 15;32(2):101-8
pubmed: 25227136
JAMA Neurol. 2019 Jun 3;:
pubmed: 31157856
J Neurotrauma. 1992 Mar;9 Suppl 1:S287-92
pubmed: 1588618
J Korean Neurosurg Soc. 2008 Nov;44(5):295-302
pubmed: 19119465
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Psychiatr Clin North Am. 2014 Mar;37(1):1-11
pubmed: 24529420
Arch Phys Med Rehabil. 2008 Dec;89(12 Suppl):S3-15
pubmed: 19081439
J Neurotrauma. 2007 Feb;24(2):270-80
pubmed: 17375991
Lancet Neurol. 2019 Jan;18(1):56-87
pubmed: 30497965
J Clin Exp Neuropsychol. 2019 Oct;41(8):775-785
pubmed: 31156042
CNS Drugs. 2016 Sep;30(9):791-806
pubmed: 27339615
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Brain Inj. 2017;31(8):1061-1068
pubmed: 28481672
J Neurotrauma. 2019 Oct 1;36(19):2753-2761
pubmed: 31017049
Clin Neurol Neurosurg. 2017 Jan;152:34-38
pubmed: 27871029
J Neurol Sci. 2008 Apr 15;267(1-2):112-9
pubmed: 18048059
J Neurotrauma. 1998 Aug;15(8):573-85
pubmed: 9726257
Neuropsychology. 2010 May;24(3):336-344
pubmed: 20438211
Arch Phys Med Rehabil. 2008 Dec;89(12 Suppl):S16-24
pubmed: 19081437
CNS Neurol Disord Drug Targets. 2015;14(5):587-99
pubmed: 25924999
Injury. 2006 Dec;37(12):1083-91
pubmed: 17092503
Neurol Sci. 2020 Feb;41(2):281-293
pubmed: 31494820
Brain Cogn. 2013 Oct;83(1):34-44
pubmed: 23872098
World Neurosurg. 2019 Oct;130:e26-e46
pubmed: 31132488
Neurosurgery. 2000 Jan;46(1):70-5; discussion 75-7
pubmed: 10626937
Neurosurgery. 2005 Dec;57(6):1173-82; discussion 1173-82
pubmed: 16331165
Brain Inj. 2018;32(12):1465-1476
pubmed: 30010431
J Clin Exp Neuropsychol. 2000 Aug;22(4):465-71
pubmed: 10923056